Deferoxamin
|
|
|
- CAS-Nr.
- 70-51-9
- Bezeichnung:
- Deferoxamin
- Englisch Name:
- Deferoxamine
- Synonyma:
- DESFEROXAMINE;dfoa;taone;entaone;ba33112;desferin;desferex;desferan;ba-29837;ba-33112
- CBNumber:
- CB8506290
- Summenformel:
- C25H48N6O8
- Molgewicht:
- 560.69
- MOL-Datei:
- 70-51-9.mol
|
Deferoxamin Eigenschaften
- Schmelzpunkt:
- 139°C
- Siedepunkt:
- 627.9°C (rough estimate)
- Dichte
- 1.2216 (rough estimate)
- Brechungsindex
- 1.5540 (estimate)
- storage temp.
- -20°C
- Aggregatzustand
- Solid
- pka
- 9.08±0.50(Predicted)
- Farbe
- White to off-white
- Major Application
- pharmaceutical
- InChIKey
- UBQYURCVBFRUQT-UHFFFAOYSA-N
- SMILES
- C(=O)(N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN)CCC(=O)NCCCCCN(O)C(=O)C
- EPA chemische Informationen
- Deferoxamine (70-51-9)
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung
|
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H317 |
Kann allergische Hautreaktionen verursachen. |
Sensibilisierung der Haut |
Kategorie 1A |
Warnung |
|
P261, P272, P280, P302+P352,P333+P313, P321, P363, P501 |
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P272 |
Kontaminierte Arbeitskleidung nicht au?erhalb des Arbeitsplatzes tragen. |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P302+P352 |
BEI BERüHRUNG MIT DER HAUT: Mit viel Wasser/... (Hersteller kann, falls zweckm??ig, ein Reinigungsmittel angeben oder, wenn Wasser eindeutig ungeeignet ist, ein alternatives Mittel empfehlen) waschen. |
| P321 |
Besondere Behandlung |
| P333+P313 |
Bei Hautreizung oder -ausschlag: ?rztlichen Rat einholen/?rztliche Hilfe hinzuziehen. |
| P363 |
Kontaminierte Kleidung vor erneutem Tragen waschen. |
| P501 |
Inhalt/Beh?lter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen. |
|
Deferoxamin Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Deferoxamine was introduced in the 1960s for chelation of
iron. It is synthesized by removing a central iron molecule
from ferrioxamine B, a compound obtained from the
microorganism Streptomyces pilosus. Deferoxamine binds to
iron from ferritin and forms ferrioxamine, a very stable and
water-soluble chelate with a characteristic reddish color.
Verwenden
Deferoxamine is used for the treatment of both acute iron
intoxication and chronic iron overload due to transfusiondependent
anemias. It has also been used in trials for malaria
treatment and for aluminum chelation in hemodialysis
patients. Studies of a rat model of intracerebral hemorrhage
have noted that deferoxamine treatment reduced oxidative
stress from iron release, indicating a possible role in preventing
damage associated with hemorrhagic strokes.
Environmental Fate
Localized infusion or injection site reactions may occur
with deferoxamine administration, such as pain, urticaria
and flushing of the skin. Hypersensitivity reactions have
been documented with both acute and chronic administration
of deferoxamine. Some of the more serious side effects
include infusion rate-related hypotension, renal insufficiency,
neurotoxicity, growth retardation, pulmonary
toxicity, and infections. Deferoxamine may induce venous
dilation when given at doses greater than 15 mg kg
-1 h
-1
leading to poor venous return, depressed cardiac output,
and eventually hypotension. Increased levels of histamine
have been noted during hypotensive episodes, although
pretreatment with antihistamines has not been shown to
stop the reaction. An acute decrease in glomerular filtration
rate and renal plasma flow secondary to hypotension is the
possible mechanism underlying the nephrotoxicity induced
by deferoxamine. Depletion of iron, translocation of copper,
and chelation of other trace elements including zinc may
interfere with critical iron-dependent enzymes, causing
oxidative damage within various tissues. These are possible
mechanisms thought to be responsible for deferoxamineinduced
neurotoxicity, growth retardation, and pulmonary
toxicity. In vitro studies have shown that deferoxamine
inhibits the synthesis of prostaglandin, hemoglobin, ferritin,
collagen, and DNA. The iron–deferoxamine complex, ferrioxamine,
is a growth factor for many bacteria and fungi.
Deferoxamine has been associated with Yersinia enterocolitica
overgrowth and fatal cases of mucormycosis with prolonged
therapy.
Deferoxamin Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Deferoxamin Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 75)Lieferanten
70-51-9(Deferoxamin)Verwandte Suche:
- deferoxamideb
- deferoxamin
- deferoxamine
- deferoxamineb
- deferoxaminum
- deferrioxamine
- deferrioxamineb
- desferan
- desferex
- desferin
- desferral
- desferriferrioxaminb
- desferrin
- desferrioxamineb
- entaone
- n-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(n-hydroxy
- n’-[5-[[4-[[5-(acetylhydroxamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pen
- n-benzoyl-ferrioxamine
- n-benzoylferrioxamineb
- nsc-527604
- ButanediaMide,N4-[5-[[4-[[5-(acetylhydroxyaMino)pentyl]aMino]-1,4-dioxobutyl]hydroxyaMino]pentyl]-N1-(5-aMinopentyl)-N1-hydroxy-
- 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(n-acetylhydroxylamino)-6,11,17,
- 22-tetraazaheptaeicosane
- 3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentone,30-amino-3,14,25-trih
- 3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentone,30-amino-3,14,25-trihyd
- 30-amino-3,14,25-trihydroxy-3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-p
- 30-amino-3,14,25-trihydroxy-3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pen
- acetamido)pentyl]carbamoyl]propionohydroxamicacid
- ba-29837
- ba33112
- ba-33112
- butanediamide,n’-(5-((4-((5-(acetylhydroxyamino)pentyl)amino)-1,4-dioxobutyl)h
- pentyl)-3-((5-(n-hydroxyacetamido)pentyl)carbamoyl)-
- taone
- tyl]-n-(5-aminopentyl)-n-hydroxybutanediamide
- ydroxyamino)pentyl)-n-(5-aminopentyl)-n-hydroxy-
- N-[5-[[4-[5-azanylpentyl(hydroxy)amino]-4-oxo-butanoyl]amino]pentyl]-N'-[5-[ethanoyl(hydroxy)amino]pentyl]-N-hydroxy-butanediamide
- N'-[5-[acetyl(hydroxy)amino]pentyl]-N-[5-[[4-[5-aminopentyl(hydroxy)amino]-4-keto-butanoyl]amino]pentyl]-N-hydroxy-succinamide
- N'-[5-[acetyl(hydroxy)amino]pentyl]-N-[5-[[4-[5-aminopentyl(hydroxy)amino]-4-oxobutanoyl]amino]pentyl]-N-hydroxybutanediamide
- N1-(5-Aminopentyl)-N1-hydroxy-N4-(5-(N-hydroxy-4-((5-(N-hydroxyacetamido)-pentyl)amino)-4-oxobuta
- DESFERROXAMINE
- N'-[5-[[4-[[5-(Acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxysuccinamide
- N'-{5-[ACETYL(HYDROXY)AMINO]PENTYL}-N-[5-({4-[(5-AMINOPENTYL)(HYDROXY)AMINO]-4-OXOBUTANOYL}AMINO)PENTYL]-N-HYDROXYSUCCINAMIDE
- N1-(5-aminopentyl)-N1-hydroxy-N4-(5-(N-hydroxy-4-((5-(N-hydroxyacetamido)pentyl)amino)-4-oxobutanamido)pentyl)succinamide
- Deferoxamine USP/EP/BP
- dfoa
- DESFEROXAMINE
- Deferoxamine B|||Desferrioxamine B
- Deferoxamine for peak identification CRS 1
- 70-51-9
- C25H48N6O8
